MoonLake Immunotherapeutics
MLTX
43 hedge funds and large institutions have $111M invested in MoonLake Immunotherapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.21% more ownership
Funds ownership: 93.83% → 94.04% (+0.21%)
4% less capital invested
Capital invested by funds: $116M → $111M (-$4.7M)
7% less funds holding
Funds holding: 46 → 43 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$798K |
| 2 |
CAC
Cowen and Company
New York
|
+$623K |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$323K |
| 4 |
D.E. Shaw & Co
New York
|
+$170K |
| 5 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$518K |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$513K |
| 3 |
Janus Henderson Group
London,
|
-$330K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$323K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$101K |
MLTX Hedge Fund Activity: Q3 2021 in Review
43 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2021, worth a combined $111M — down 4.1% from $116M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MLTX and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $798K. The largest seller was Logos Global Management, exiting entirely with an estimated $518K sold.
- 43 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2021, down from 46 in Q2 2021.
- Funds reported $111M of MoonLake Immunotherapeutics stock for Q3 2021, down 4.1% quarter-over-quarter.
- 1 fund opened new MoonLake Immunotherapeutics positions in Q3 2021 and 4 closed out, a net change of -3 holders.
- The largest MoonLake Immunotherapeutics buyer in Q3 2021 was STALEY CAPITAL ADVISERS, an estimated $798K added.
- The largest MoonLake Immunotherapeutics seller in Q3 2021 was Logos Global Management, an estimated $518K sold.
Based on aggregated 13F filings for Q3 2021.